Bacteriophage as a New Weapon to Fight Drug-resistant Bacteria

DRUG DEVELOPMENT TRACK

Offers both CME & CPE Credit
UAN #JA4008220-0000-20-031-H01-P
ACPE – 1.5 CONTACT HOURS/KNOWLEDGE-BASED

CHAIR:
Stephan Schmidt, PhD, Certara Professor, Associate Professor & Director, Ctr for Pharmacometrics & Systems Pharmacology, Pharmaceutics Lake Nona, Univ of Florida

TARGET AUDIENCE:
This Symposium will be useful for drug discovery and development scientists, clinical pharmacologists, clinician scientists and regulatory scientists.

GOALS & OBJECTIVES:
Following the completion of this activity, the learner will be able to:

1. Review the current challenges in treating multidrug-resistant (MDR) bacterial infections using antibiotics and the need for developing efficacious non-antibiotic antimicrobial therapies;
2. Explain the mechanism of bacteriophage therapy;
3. Discuss the recent progress of bacteriophage therapy in treating MDR bacterial infections;
4. Evaluate the future potential of bacteriophage therapy in treating MDR bacterial infections.

Adaptive Phage Therapy for the Treatment of Drug-resistant Bacterial Infections
Carl R. Merril, MD, Scientist Emeritus, National Inst of Health & Chief Scientific Officer, Adaptive Phage Therapeutics Inc

Pharmacokinetics/Pharmacodynamics of Traditional Antimicrobial Drugs: Lessons to Be Learned for Bacteriophages
Stephan Schmidt, PhD, Certara Professor, Associate Professor & Director, Ctr for Pharmacometrics & Systems Pharmacology, Pharmaceutics Lake Nona, Univ of Florida

Next Generation Phage Detection and Identification
Mike Marquet, MS, PhD Student, University Hosp Jena

Faculty Panel Discussion, Questions & Answers, Learner Feedback & Evaluation